BACKGROUND: Advanced melanomas (non-resectable Stage-III/IV) are fatal, with few
effective treatments. It remains unclear if other drugs offer improvements over the standard …

The number of melanoma cases worldwide is increasing faster than any other cancer and
remains one of the most treatment-refractory malignancies. Despite decades of clinical trials …

Since dacarbazine was approved for treating metastatic melanoma in the 1970s, numerous
studies have evaluated whether different schedules and dacarbazine-based combinations …

Background: Melanoma is one of the most aggressive cancers, and it is estimated that
76,250 men and women will be diagnosed with melanoma of the skin in the USA in 2012 …

Background Malignant melanoma is the most aggressive and deadly form of skin cancer.
Dacarbazine (DTIC) has been the approved first-line treatment for metastatic melanoma in …

Opinion statement The rapid increase in incidence of malignant melanoma has not been
associated with better therapeutic options over the years. Single-agent chemotherapy or …

Dacarbazine (DTIC) has been the mainstay of chemotherapy for metastatic melanoma for
over two decades, but only 15%–20% of patients respond and benefit is usually transient …

It is currently unclear whether any combination therapy for the treatment of metastatic
melanoma is superior to standard single-agent dacarbazine (DTIC) in terms of tumour …

Background Recent phase 3 trials have shown an overall survival benefit in metastatic
melanoma. We aimed to assess whether progression-free survival (PFS) could be regarded …

Background Systemic therapies for metastatic cutaneous melanoma, the most aggressive of
all skin cancers, remain disappointing. Few lasting remissions are achieved and the …